AFT Pharmaceuticals - Maxigesic IV expands into East European markets
AFT Pharmaceuticals has announced an exclusive licensing and distribution agreement for the Maxigesic intravenous (IV) formulation with Salus...
227 Views
AFT Pharmaceuticals - Progressive outlook for CY23
AFT Pharmaceuticals has presented its key CY22 highlights and strategic priorities for CY23 in a letter to investors. In addition to new product...
425 Views
AFT Pharmaceuticals: 1H23 Result — A Few Sniffles
AFT Pharmaceuticals' (AFT) 1H23 result highlighted ongoing strong underlying revenue momentum which was ahead of our expectations, but this was...
282 Views
AFT Pharmaceuticals (AFT): 1H23 Result – Initial Impressions
AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m...
268 Views
AFT Pharmaceuticals - H123 focused on portfolio expansion
AFT reported strong post COVID-19 revenue momentum in H123 (NZ$65.8m, 18.4% y-o-y growth), driven by robust organic growth across all regions,...
663 Views